BioCentury | Sep 11, 2020
Product Development

Pfizer’s MacKenzie: Other diseases deserve the same acceleration as COVID-19: a BioCentury audio interview

Pfizer’s Rod MacKenzie says the collaborations and accelerated timelines taking place during COVID-19 are causing introspection in pharmas for how they operate, and for how they can push for regulators...
BioCentury | Feb 18, 2020
Product Development

Riptide peptide turns TAMs proinflammatory

Riptide has lifted the curtain on its first immuno-oncology program, RP-182, which comprises an engineered peptide that reprograms tumor-associated macrophages to become proinflammatory. Strategies to convert immunosuppressive macrophages into proinflammatory cells have been gaining momentum...
BioCentury | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BioCentury | Apr 30, 2019
Tools & Techniques

Bioethicist Caplan makes case against germline editing moratorium

Outrage over He Jiankui’s unethical use of CRISPR to modify embryos that resulted in the birth of two gene edited babies has fueled loud demands from scientists, ethicists, physicians and politicians for moratoria on human...
BioCentury | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
BioCentury | Jan 8, 2019
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) In vitro and mouse studies identified an NR1D1 agonist that could help treat MS. Optimization and in vitro binding assays of analogs of a previously reported benzohydrazide-based NR1D1 agonist yielded a...
BioCentury | Sep 21, 2018
Company News

Celenex takeout first of several expected Amicus gene therapy deals

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...
BioCentury | Sep 20, 2018
Company News

Celenex takeout first of several planned gene therapy deals for Amicus

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...
BioCentury | Sep 7, 2018
Clinical News

Abivax's ABX464 improves mucosal healing, Mayo Score in Phase IIa for UC

Abivax S.A. (Euronext:ABVX) said ABX464 improved mucosal healing rate (50% vs. 11%, p=0.03) and reduced partial (62% vs. 32%, p<0.02) and total Mayo Scores (53% vs. 37%, p<0.03) at eight weeks vs. placebo in 29...
Items per page:
1 - 10 of 407